Welcome to our dedicated page for HARROW SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HARROW's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HARROW's regulatory disclosures and financial reporting.
Harrow, Inc. reported the results of its 2026 annual stockholder meeting. A total of 37,273,420 shares were entitled to vote, and 29,830,973 shares were present or represented by proxy. All four director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Harrow, Inc. furnished a corporate presentation as an exhibit to a current report. The presentation, dated June 2026, may be used by management at investor conferences and meetings with analysts and other interested parties. The material is provided under Regulation FD as supplemental information.
The company states that the presentation and related disclosure are furnished rather than filed, which means they are not subject to certain liability provisions and are not automatically incorporated into other securities filings unless specifically referenced.
Harrow, Inc. director Adrienne L. Graves bought 1,000 shares of common stock in an open-market transaction at $31.07 per share. This purchase on May 18, 2026 brings her directly held stake to 1,000 shares, indicating a new personal equity position in the company.
Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. Following this transaction, Silvernail directly owns 1,000 common shares, indicating this filing reflects an initial reported stake rather than a large position change.
Shojaei Amir reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. reported that Chief Scientific Officer Amir Shojaei received a grant of 10,000 restricted stock units, each representing a right to one share of common stock. These RSUs vest in full on May 15, 2029, contingent on his continued service, and reflect compensation rather than open-market trading.
Harrow, Inc.'s Chief Executive Officer Mark L. Baum reported an open-market purchase of 10,000 shares of common stock at a weighted average price of $30.20 per share. After this transaction, he directly owns 2,996,130 shares. The filing notes the shares were bought in multiple trades between $30.18 and $30.34 per share.
Harrow, Inc.’s president and CFO, Andrew R. Boll, bought additional company stock. On May 14, 2026, he made open-market purchases totaling 3,500 shares of Harrow common stock at a price of $29.90 per share. After these transactions, he directly owns 814,679 Harrow common shares.
The filing notes the 3,500 shares reflect two separate open-market trades on that date, each executed at $29.90 per share, and indicates that detailed trade information is available upon request.
Harrow, Inc. reported softer results for the quarter ended March 31, 2026. Total revenues were $44.2 million, down from $47.8 million a year earlier, as branded product sales grew but compounding revenues declined sharply, including the prior discontinuation of Klarity-C.
Branded revenue rose to $30.7 million, led by VEVYE at $20.9 million, while IHEEZO sales fell. Compounding revenue dropped to $13.5 million. Higher selling, general and administrative spending and increased R&D pushed the net loss to $27.6 million, compared with $17.8 million in the prior-year quarter.
Harrow ended the quarter with $94.6 million in cash and cash equivalents, helped by issuing an additional $50 million of 8.625% Senior Notes due 2030, bringing total notes payable, net, to $292.1 million. Operating cash flow swung to an outflow of $9.0 million from an inflow of $19.7 million a year earlier.
Harrow, Inc. ownership update: a joint Schedule 13G/A shows Opaleye entities and James Silverman report beneficial ownership of 2,832,230 shares of Harrow common stock. The filing states this equals 7.61% of the class. Opaleye, L.P. separately reports 2,805,000 shares (7.53%), based on 37,229,705 shares outstanding as of February 25, 2026.
The statement clarifies shared voting and dispositive power over the reported shares and is signed by James Silverman on behalf of all reporting persons.
Harrow, Inc. reported first-quarter 2026 revenue of $44.2 million, down 8% from $47.8 million a year earlier, mainly due to VEVYE gross-to-net adjustments and softer compounded product sales. Gross margin declined to 61% from 68%, and the company posted a net loss of $27.6 million, wider than the prior-year loss of $17.8 million. Adjusted EBITDA was a loss of $12.7 million versus a $2.0 million loss last year, reflecting heavier commercial and R&D investment.
Despite weaker reported earnings, demand for key brands remained strong. VEVYE generated $20.9 million in revenue after an estimated $8 million non-recurring gross-to-net reduction and achieved about 14% branded dry eye market share, surpassing XIIDRA on monthly total prescriptions. IHEEZO unit demand rose 18% year over year, and TRIESENCE demand more than doubled, marking a sixth straight growth quarter.
Harrow ended the quarter with $94.6 million in cash and reiterated its full-year 2026 guidance for revenue of $350–$365 million and Adjusted EBITDA of $80–$100 million, with performance weighted to the second half. Second-quarter 2026 revenue is expected between $71 million and $81 million, supported by an expanded sales force, growing prescription trends for VEVYE, and increasing adoption of IHEEZO and TRIESENCE.